CTN-0102-XR: Rural Expansion of Medication Treatment for Opioid Use Disorder: Randomized Controlled Pilot Trial of Extended-release Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings (NIH HEAL Initiative)

Yih-Ing Hser, PhD
Co-Principal Investigator

University of California, Los Angeles

Larissa Mooney, MD
Co-Principal Investigator

University of California, Los Angeles

This randomized, open-label pilot study will assess the feasibility, acceptability, and effectiveness of extended-release buprenorphine (XR-BUP, CAM2038), compared with sublingual buprenorphine-naloxone (SL-BUP) for treatment of opioid use disorder (OUD) among rural patients.  Relative effectiveness of XR-BUP vs SL-BUP in rural populations with OUD has not been subjected to research, and this project seeks to rapidly develop new knowledge on the issues to support future large-scale trials. Findings will suggest possible next steps for additional research and will inform scaling of the implementation to improve capacity to utilize extended-release MOUD and increase MOUD access and uptake of extended-release MOUD in rural communities. 

Funded by the NIH HEAL Initiative®

Related Resources

    Node Involvement

    Lead Node(s):

  • Greater Southern California Node